Last reviewed · How we verify
Sirolimus Oral Tablet
At a glance
| Generic name | Sirolimus Oral Tablet |
|---|---|
| Also known as | Rapamycin, Rapamune, Oral rapamycine |
| Sponsor | Columbia University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma (PHASE1, PHASE2)
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (PHASE2, PHASE3)
- Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (PHASE2)
- Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms (PHASE2)
- Everolimus Trial in Laryngotracheal Stenosis (EARLY_PHASE1)
- Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) (PHASE1, PHASE2)
- Siplizumab for Sickle Cell Disease Transplant (PHASE1, PHASE2)
- Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sirolimus Oral Tablet CI brief — competitive landscape report
- Sirolimus Oral Tablet updates RSS · CI watch RSS
- Columbia University portfolio CI